



Original Article  
DESIGN AND EVALUATION OF BUCCOADHESIVE CONTROLLED RELEASE FORMULATIONS OF 
PROCHLORPERAZINE MALEATE 
 
SONIA PANDEY*1, RITESH R. SHAH1, ARTI GUPTA1, B. ARUL2 
1Department of Pharmaceutics, Maliba Pharmacy College, Bardoli, India, 2
sonia.pandey@utu.ac.in
Vinayaka Mission College of Pharmacy, Salem, Tamilnadu 
Email:  
 Received: 04 Aug 2015 Revised and Accepted: 02 Dec 2015 
ABSTRACT 
Objective: The Purpose of this work was to design mucoadhesive tablets of prochlorperazine maleate to release the drug in buccal cavity for an 
extended period of time in order to avoid the first-pass metabolism.  
Methods: Six formulations were prepared using different polymer like Xanthan gum, Locust bean gum, Carbopol 974P NF, HPMC K100MCR, Polyox-
WSR301 and Gantrez AN139 as a mucoadhesive and controlled release agents. The formulations were tested for content uniformity, thickness, 
weight variation, friability, in vitro drug release, in-vitro bio-adhesion, swelling index and residence time.  
Results: Drug excipient compatibility studies performed using DSC. The DSC studies revealed endothermic peak at 200o–205o
Keywords: Buccoadhesive tablets, Prochlorperazine maleate, Mucoadhesive polymer. 
C for Prochlorperazine 
maleate. Similarly endothermic peaks were obtained for separate excipient when heated in the range of 50-300 °C indicating their melting points. There 
was no separate peak observed when the drug was mixed with the different polymers like Xanthan gum, locust bean gum, Carbopol 974 P, HPMC K100 
MCR, Gantrez AN139 and Polyox-WSR301 in ratio (1:1) indicating that no interaction took place between drug and polymers used in the study. 
Dissolution studies of the tablets of the optimized batch (BDS-6) containing Carbopol 974P (CP) and HPMC K100 MCR showed extended release 90.65% 
up to 24 hr. The bioadhesive force of optimized formulation is 12.18±.011 gm and the maximum swelling index was observed in 3.87±.0057 h.  
Conclusion: From the study it can be concluded that formulation BDS-6 containing Carbopol and HPMC K100 MCR give a promising result for 
sustained release action of PrM.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) 
 
INTRODUCTION 
Buccal drug delivery system (BDS) has been considered as an 
alternative to oral dosing for compounds subjected to degradation in 
the gastrointestinal tract or to hepatic first pass metabolism [1]. Buccal 
drug delivery offers a safer mode of drug utilization since drug 
absorption can be promptly terminated in cases of toxicity by 
removing the dosage form from the buccal cavity [2]. The advances in 
bioadhesive and controlled release technology have stimulated a 
renewal of interest in the delivery of drugs to, or via, the buccal route. 
Buccal drug delivery (BBD) devices can now be designed to remain in 
contact with the oral mucosa while providing controlled release 
characteristics over a prolonged period of time. A combination of these 
two attributes can be achieved by the use of suitable bioadhesive 
materials. Appropriate materials for the bioadhesive drug delivery 
consist mainly of hydrogel-forming polymers [3].  
Prochlorperazine maleate (PrM) is a piperazine phenothiazine 
derivative with antipsychotic, antiemetic and weak sedative activity. 
PrM is well absorbed from the gastrointestinal tract PrM distributes to 
most body tissues with high concentrations being distributed into both 
liver and spleen. PrM enters the enterohepatic circulation and is 
excreted chiefly in the feces. The low oral bioavailability 16% is due to 
the high first pass metabolism [4]. Since buccal route bypasses first 
pass effect, the dose of the drug could be decreased by 50%. The drug 
dosage regimen is usually three to four times a day because of it’s 
short half-life [5] which makes it a good candidate for buccal and 
controlled drug delivery. The Proper combination of suitable 
mucoadhesive polymer would allow the desired mucoadhesion and 
extended release of the drug. The various polymers considered alone 
and in combination suitable for the development of bioadhesive 
extended release delivery like cellulosic and polyacrylates derivatives 
(hydroxypropyl-methylcellulose and Carbopol) natural gums (xanthan 
gum and locust bean gum) Gantrez A139 and Polyox-WSR301 (PEO). 
PEO is the fastest hydrating water soluble polymer among hydrophilic 
polymers [6]. Xanthan gum is a hydrophilic, anionic heteropoly-
saccharide whereas Locust bean gum is a nonionic polysaccharide and 
its hydration process is independent of pH. The drug release was 
slower from the matrices which were composed of both xanthan gum 
and locust bean gum compared with the tablets whose composition 
was only locust bean gum and xanthan gum [7]. Hydroxypropyl 
methylcellulose (HPMC), a semisynthetic derivative of cellulose, has its 
popularity for the formulation of controlled release (CR) dosage forms 
as a swellable and hydrophilic polymer. Carbopol polymers have been 
used as mucoadhesives. Carbopol polymers are high molecular weight, 
crosslinked, acrylic acid-based polymers and carbopol 974P are cross-
linked with allyl pentaerythritol that are polymerized in ethyl acetate 
[8]. Gantrez AN-139 copolymer of methyl vinyl ether and maleic 
anhydride and methyl vinyl ether and maleic acid, respectively 
(PMVE/MAH) and PMVE/MA, with molecular masses of 1,080,000 [9]. 
Effect of polymer concentration on mucoadhesion and release pattern 
was also studied. The purpose of this work is to design mucoadhesive 
tablets to release the drug in buccal cavity for an extended period of 
time in order to facilitate the intimate contact with the underlying 
absorption surface, to avoid the first-pass metabolism, for better 
bioavailability, to reduce the dosing frequency and to improve patient 
compliance. 
MATERIALS AND METHODS 
Materials 
Prochlorperazine maleate (PrM), HPMC K100MCR, Carbopl 974P, 
locust bean gum and Xanthan gum were obtained as a gift sample 
from Alembic pharmaceutical Vadodara. PEO WSR 205 was 
purchased from Dow chemicals, India. Gantrez AN-139 was 
purchased from Sigma-Aldrich. All other chemicals and reagents 
used were of analytical grade.  
Drug excipient compatibility study 
Differential scanning calorimetry (DSC) 
The samples were sealed in aluminum pans, and DSC thermo grams 
were recorded at a heating rate of 10C/min from 50 ○C to 300 ○C 
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temperature range. A nitrogen purge was maintained throughout 
runs and baseline optimization was performed before each run. 
Preparation of mucoadhesive tablets 
Various mucoadhesive tablet formulations of PrM were formulated 
with different water soluble polymers like Xanthan gum, Locust 
been gum, Carbopol 974P NF, HPMC K100MCR, Polyox-WSR301, 
Gantrez AN139 as a mucoadhesive agent, polyvinylpyrrolidone in 
Isopropyl alcohol (IPA) as a binder solution, sucrose as a diluent as 
well as sweetener, magnesium stearate as a lubricant and talc as a 
glidant. Tablets weighing 60 mg containing 5 mg of PrM were 
compressed using tableting machines (rimek minipress) employing 
a 5.5 mm flat punch without brake line. Compression force was 
adjusted to the hardness of 4-5 kg/cm2
After ejection, the tablets were stored over silica gel in a desiccator for 24 
h to allow for elastic recovery and hardening. Different mucoadhesive 
agents were studied to check the effect on the mucoadhesive force, 
swelling index and % drug release. The different batches were prepared 
as mentioned in table 1. Prepared mucoadhesive tablets were evaluated 
for their physical and mechanical properties like weight uniformity, 
content uniformity, hardness, friability, diameter, thickness, bio-
adhesion force, swelling index and in vitro drug release study. 
  
Table 1: Composition of mucoadhesive tablets with different mucoadhesive agents 
.  
Ingredient BDS-1 * BDS-2 BDS-3 BDS-4 BDS-5 BDS-6 
Xanthan gum 4.5 - - - - - 
Locust been gum 4.5 - - - - - 
Carbopol 974P - 5 - - - 5 
HPMC K100 MCR - - 5 - - 5 
Gantrez AN139 - - - 5 - - 
Polyox-WSR301 - - - - 5 - 
Prochlorperazine maleate 5 5 5 5 5 5 
PVP K29/30 3 3 3 3 3 3 
Sucrose 41.5 45.5 45.5 45.5 45.5 40.5 
Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 
Talc 1 1 1 1 1 1 
Total wt  60 60 60 60 60 60 
*
 
Measurement of bio-adhesion force 
Indicates the quantity in mg. 
The force of adhesion for each formulation was measured by a specially 
designed apparatus by referring to the literature [10]. Apparatus is 
shown in fig. 1. A string was wound over two pulleys and connected to a 
pin stuck to the surface of the mucoadhesive tablet. The other surface of 
each tablet was stuck to sieve no (120) by the wetting procedure. An 
empty bottle was connected to the other side of the string. The adhesion 
force was measured by addition of water to this bottle. The weight of 
water as a measure for the force of adhesion was determined.  
 
 
Fig. 1: Measurement of bioadhesion force, A= Plastic bottle B= 
Pipette C= Pulley D= Thread E= Pin F= 120 No Sieve, G= Buccal 
tablet H= stainless steel I= Stand  
 
Measurement of swelling index (SI)  
Tablets were weighed individually along with the Petri dish (W1).10 
ml of phosphate buffer (pH6.8) was added to each Petri dish. At a 
regular interval (0.5, 1, 2, 3, & 4 h) the excess amount of phosphate 
buffer was removed by using tissue paper. The swollen tablets were 
reweighed (W2) and SI was calculated using the following formula.  
 
Where, S. I = swelling index, W1= initial weight of tablet, W2
11
= weight 
at time‘t’ [ ]  
Determination of residence time 
The in-vitro residence time was determined using a locally modified 
USP disintegration apparatus. The disintegration medium was 800 ml 
isotonic phosphate buffer solution pH 6.8, maintained at 37 °C±1 °C. A 
segment of goat buccal mucosa was glued to glass slide, attached to 
glass slab which is vertically attached to the apparatus. The tablet was 
hydrated from one surface using a little amount of isotonic phosphate 
buffer solution, and then the hydrated surface was brought into contact 
with the mucosal membrane. The glass slab was vertically fixed to the 
apparatus and allowed move up and down so that the tablet was 
completely immersed into the solution at the lowest point and was out at 
the highest point. The time necessary for complete erosion or 
detachment of the tablet from the mucosal surface were recorded [12].  
In vitro drug release study 
The USP V (Disc cover paddle) method was employed for the in-vitro 
dissolution studies. The dissolution medium was, 500 ml of isotonic 
phosphate buffer solution pH 6.8. The rate of stirring was 100 rpm. 
The temperature was maintained at 37 °C±0.5 °C for a period of 24 h. 
At appropriate time interval (1, 2, 4, 6, 8, 12, 16 and 24 hr), 10 ml of 
sample was taken and filtered. In the dissolution media, 10 ml of 
fresh dissolution fluid was added after each withdrawal in order to 
maintain a constant volume. The samples were assayed at 262 nm 
by 1st Derivative Spectroscopy [13-15]. 
Drug release kinetics 
Release data were analyzed using the following equation:  
 
Where, Mt/M∞
For non-fickian release, the value of n falls between 0.5 and 1.0; while, 
on the case of fickian diffusion, n = 0.5; for Zero order release (case II 
transport), n = 1; and for super case II transport, n is greater than 1. 
The values of ‘n’ were estimated by linear regression of log (M
: is the fractional release of drug, 
t: Denotes the release time, 
K: Constant incorporating structural and geometrical characteristics 
of the device  
n: Diffusional exponent that characterized the type of release 




versus log (t) of different formulations are shown in table 2. This 
model used, when the release mechanism is not known or when more 
than one type of release phenomenon could be involved [ 7]. 
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RESULTS AND DISCUSSION 
Compatibility studies of drug: polymer 
The DSC thermo grams are represented as fig. no 2(a-e). According 
to the functional category, the drug and excipient are mixed in an 
appropriate ratio in a mortar for 5-10 min and then transferred the 
amount in amber colored glass vials. Samples in amber glass vials 
were loaded in the 60 o
The DSC studies revealed endothermic peak at 200
C chamber. Initial samples were evaluated for 
incompatibility studies by differential scanning calorimetry (DSC). 
The samples were checked for physical changes such as lump 
formation and color change after two weeks. 
o–205 o
Evaluation of mucoadhesive tablets 
C for PrM. 
Similarly, Endothermic peak were obtained for separate excipient 
when heated in the range of 50-300 °C indicating their melting 
points. There was no separate peak seen when the drug was mixed 
with the polymer in a ratio indicating that there is no interaction 
between drug and polymers used in the study. No significant change 
in onset values in the DSC curve indicates that the PrM is stable with 
all polymer investigated.  
Physicochemical characterization of PrM revealed that the drug is a 
slightly bitter, off-white amorphous powder, with a melting point 
range from 200o–205 oC. The assay was found to be 97% w/w and the 
percentage loss on drying was 1.55%w/w. The bulk density and 
tapped density of the drug was found to be 0.309 gm/ml and 0.486 
gm/ml respectively. The compressibility index and Hauser’s ratio of 
the drug were found to be 36.419% and 1.572 respectively, which 
showed that the compressibility of the PrM was poor. The particle size 
analysis was done by sieve method which revealed that higher % of 
the particles were of the size 180 µm retained. All the tablet 
parameters as weight variation, thickness, hardness, friability were 
found within the limits and comply as per official limits (wherever 
applicable) results are shown in table 2. The bioadhesion force of all 
the formulations is shown in table 3. The bioadhesion force of 
optimized formulation is 12.18±.011 gm. The swelling index of the 
optimized batch was found to be 3.27±.0057 and results are shown in 
fig. 3. Residence time of the optimized batch was found to be 9.45 hr 
and values of all the formulation shown in table 4. The kinetic studies 
showed the non-fickian diffusion. The results are listed in table 5. 
 
 
Fig. 2(a-g): DSC thermograms of pure grams of pure drug and along with the polymer 
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Table 2: Physical parameter of buccoadhesive tablets 
Batch no. Weight of tablet (mg) 
(n=20) 




Friability (%)(n=20) % Assay(w/w) 
(n=20) 
BDS-1 60.05±0.73 4.41±0.66 2.16±0.03 0.15±0.5 100±0.31 
BDS-2 60.26±0.65 4.37±0.61 2.17±0.04 0.09±0.39 93.47±0.45 
BDS-3 60.06±0.77 4.57±0.46 2.18±0.05 0.09±0.56 93.47±0.03 
BDS-4 60.13±0.77 4.54±0.59 2.19±0.03 0.12±0.13 93.47±0.01 
BDS-5 60.32±0.95 4.61±0.51 2.17±0.05 0.09±0.02 95.65±0.18 
BDS-6 60.42±0.80 4.43±0.56 2.18±0.06 0.09±0.03 95.65±0.04 
All Value expressed as mean±SD  
 
Table 3: Bioadhesion force 
Formulation Bioadhesive force (gm) 
BDS-1 16.00±.12 
BDS-2 11.92±.06 
BDS-3 Not obtained 
BDS-4 Not obtained 
BDS-5 7.60±.18 
BDS-6 12.18±.011 
All Value expressed as mean±SD (n=3) 
 
Table 4: Residence time (h) of all the batches 
 Residence time(h)  
Batch no. BDS-1 BDS-2 BDS-3 BDS-4 BDS-5 BDS-6 
 9.45±0.10 9.67±0.42  Not performed  Not performed   8.88±0.39 >10 
 All Value expressed as mean±SD (n=3) 
 
Table 5: Kinetic coefficients estimated values of n (Diffusional Exponent) and r2 (Correlation coefficient) Mt/M∝ )
Batch code 
Vs Log (T) 
Kinetic parameters for peppas model 
 n  (Diffusional exponent)  r2 (Correlation coefficient) 
BDS-1 0.7399 0.9726 
BDS-2 0.7053 0.9858 
BDS-3 0.6698 0.9978 
BDS-4 0.5886 0.9940 
BDS-5 0.5945 0.9853 




Fig. 3: Graphical representation of swelling index of prepared 
buccoadhesive Prochlorperazine maleate tablets (BDS-1 to BDS-6) 
 
The result of bioadhesive force study as presented in table no.3 
showed 16 gm, 11.93 gm, 7.60 gm, and 12.18 of BDS-1, BDS-2, BDS-5 
and BDS-6 respectively. BDS-1 formulation containing xanthan gum 
and locust been gum showed highest bioadhesive force (16 gm) may 
be due to the high interlocking property of xanthan gum and locust 
been gum because Locust bean gum is a galacto mannan composed of 
a 1-4-linked-b-D-mannan backbone with 1-6-linked-a-D-galactose side 
groups so Xanthan gum interacts with galacto mannans to form mixed 
gels with high viscosity at low-total-polysaccharide concentrations 
[18]. The sufficient bio-adhesion value was not observed in BDS-3 and 
BDS-4 that may be due to the presence of HPMC K100MCR and 
Gantrez AN139 respectively, so these formulation are not considered 
for further studies The least bioadhesive force value was proposed by 
BDS-5 formulation containing only Polyox-WSR301.  
The swelling behavior of differently formulated tablets as a function 
of time was shown in fig. 3. The appropriate swelling behavior of a 
buccal adhesive system is an essential property for uniform and 
prolonged drug release. The swelling index increased with time as 
the weight gain by the tablet was increased proportionally with the 
rate of hydration. The maximum swelling was obtained in 4 h (BDS-
6), after which polymer starting eroding slowly in the medium. 
During the swelling study, two phases such as swelling phase 
(increase in weight) and the degradation phase (reduction in 
weight) were observed [19]. The maximum swelling was observed 
in formulation BDS-6 containing Carbopol 974P NF and HPMC K100 
MCR. BDS-5 formulation showed least swelling index in comparison 
to other formulation. The linearity in the swelling index shows the 
sustained release of the drug. The tablets of all batches except BDS 
6-BDS 1, BDS 2 and BDS 5 showed the moderate residence time 
(around 8.8 h). Tablets of batch BDS 6 showed residence more than 
10 hr; reason might be the presence of carbopol 934P and HPMC 
K100 MCR [19]. The in-vitro release study did not showed the 
satisfactory sustained release of PrM from all formulation. 
Comparative dissolution profiles of all batches BDS-1 to BDS-6 were 
shown in fig. 4. 
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Fig. 4: Comparative drug release profile prepared 
buccoadhesive PrM tablets of all batches (BDS-1 to BDS-6) 
 
The burst release was observed in tablets of batches BDS-4 and BDS 5 
containing Gantrez AN139, Polyox WSR 301 respectively because these 
polymers did not show sufficient bioadhesive and swelling properties as 
reflected from results, so drug release cannot be controlled with these 
polymers. From the in-vitro release study, it was also concluded that 
formulation BDS-2 and 3 showed slower release compared to batch BDS-
4 and 5 but not extendable up to 24 h. BDS-2 and 3 containing CP and 
HPMC released the whole drug within 16 hr. BDS-6 considered as 
optimized batch release was slow and extendable up to 24 h because CP 
and HPMC are hydrophilic swellable polymer matrices; they are able to 
form a viscous gel layer; which controls the drug release via diffusion 
through the gel and erosion of the gel layer [19]. Batch BDS-6 was 
considered for further studies based on swelling study, bio-adhesion 
force, mucoadhesion time and drug release study. The data obtained 
from the release kinetic study shows all the ‘n’ values in between 0.5 to 1; 
indicating non-fickian release kinetics. 
CONCLUSION 
The mucoadhesive tablet formulation BDS-6 containing CP and 
HPMC give a promising result for sustained release action of PrM 
with adequate swelling, bio-adhesion force, suitable residence time, 
and, it reduces the polymer loss, along with sustained release of drug 
from the mucoadhesive tablets.  
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